Trials / Completed
CompletedNCT05906628
Topical Ruxolitinib Evaluation in Chronic Hand Eczema
A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 186 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement (IGA) of CHE score 3 or 4).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ruxolitinib cream | Ruxolitinib cream is a topical formulation applied as a thin film to affected areas. |
| DRUG | Vehicle | Vehicle cream is a topical formulation applied as a thin film to affected areas. |
Timeline
- Start date
- 2023-07-31
- Primary completion
- 2024-07-15
- Completion
- 2024-12-13
- First posted
- 2023-06-18
- Last updated
- 2025-07-31
- Results posted
- 2025-07-31
Locations
36 sites across 4 countries: United States, Canada, Germany, Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05906628. Inclusion in this directory is not an endorsement.